Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP224892.RAYJQPF-pzuAIFVCFSINEmGHrFS6ul6KmWFwM5UQVHVxk130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP224892.RAYJQPF-pzuAIFVCFSINEmGHrFS6ul6KmWFwM5UQVHVxk130_provenance.
• NP225278.RAYBCvul8px4fd8j8A3bGdR7UvQiUjtwY8sAcrk3SHBBA130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP225278.RAYBCvul8px4fd8j8A3bGdR7UvQiUjtwY8sAcrk3SHBBA130_provenance.
• NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_provenance.
• NP270610.RApOi9r8S2eLEIx4TbU1SuI3syo7dKct9Dta_rm4PkikM130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP270610.RApOi9r8S2eLEIx4TbU1SuI3syo7dKct9Dta_rm4PkikM130_provenance.
• NP1093332.RAconHaK92fkEL61wyDjzHYu_85acUA19xkj7GrAnGgYw130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093332.RAconHaK92fkEL61wyDjzHYu_85acUA19xkj7GrAnGgYw130_provenance.
• NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_provenance.
• NP320985.RAvjZ2DDQuY-McHH6v_ZWPEblL0brVRaNgpEb-ZNLE2hs130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP320985.RAvjZ2DDQuY-McHH6v_ZWPEblL0brVRaNgpEb-ZNLE2hs130_provenance.
• NP271410.RApBqOv_3ArqDrbSqKNV81p_pkGHng5KXCANgEijgkGeg130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP271410.RApBqOv_3ArqDrbSqKNV81p_pkGHng5KXCANgEijgkGeg130_provenance.
• NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_provenance.
• NP225145.RAj2ihaDagrmooy_1c1f1SKGIGYRIdXCN20cyTz026l_M130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP225145.RAj2ihaDagrmooy_1c1f1SKGIGYRIdXCN20cyTz026l_M130_provenance.
• NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP225423.RAp6TOKgSomeXKGFaDDsd1tcNArY6R5q-LyADPeIRCIW0130_provenance.
• NP1093333.RAtsRTv7Zp-UnjkWYm9sCXGqu6bjwo6dTQuPMmnNKUGY8130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093333.RAtsRTv7Zp-UnjkWYm9sCXGqu6bjwo6dTQuPMmnNKUGY8130_provenance.
• NP1093337.RAtSGGK3N85yQtFKGyjGIy1YfcLN5dtP5cYy1sOEhm73c130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093337.RAtSGGK3N85yQtFKGyjGIy1YfcLN5dtP5cYy1sOEhm73c130_provenance.
• NP1093338.RAprRDGVVzUqUrC3Xe-ArVdfl4piSB937itZs-8KBWfuU130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093338.RAprRDGVVzUqUrC3Xe-ArVdfl4piSB937itZs-8KBWfuU130_provenance.
• NP1093339.RAkqD8S8FjOwA1fTaLmF3GrBYBXKIRuY0KQ7mrK5Hd8SE130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093339.RAkqD8S8FjOwA1fTaLmF3GrBYBXKIRuY0KQ7mrK5Hd8SE130_provenance.
• NP1093342.RAp_SFR349nzQRV19sm7S2pZkPWZpv-bfj8vyZXJZAB14130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093342.RAp_SFR349nzQRV19sm7S2pZkPWZpv-bfj8vyZXJZAB14130_provenance.
• NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP320919.RA69a4c-z6ml58PO9VhgT6QBaOjyaocrLCefy8AEEcv1Q130_provenance.
• NP321078.RA7NLGye9iB8VlkSTPFJJ6BJQtXCzptER4i3Sw7TdTZ4M130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP321078.RA7NLGye9iB8VlkSTPFJJ6BJQtXCzptER4i3Sw7TdTZ4M130_provenance.
• NP271160.RA9O8JCv8cdYJLpBLInExD2GHqkMYEIRJnS7O-uNgQE_o130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP271160.RA9O8JCv8cdYJLpBLInExD2GHqkMYEIRJnS7O-uNgQE_o130_provenance.
• NP321030.RAFLWQOyVhOVEEiuePVdM5EJLY7C-55ftTGGIFiBXMizU130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP321030.RAFLWQOyVhOVEEiuePVdM5EJLY7C-55ftTGGIFiBXMizU130_provenance.
• NP321066.RAOUYMjGGNjLcgIxmAQoOXmyc96TPq29hBqXqW3r1NWPM130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP321066.RAOUYMjGGNjLcgIxmAQoOXmyc96TPq29hBqXqW3r1NWPM130_provenance.
• NP1093340.RANybVysCbwq_zLQyShM1oGC_bRLstIl7nJcxQ2p-U19c130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093340.RANybVysCbwq_zLQyShM1oGC_bRLstIl7nJcxQ2p-U19c130_provenance.
• NP1093341.RALdl3h9-SDFjS4jG3WuVFnrlAVFpWQmwcA7yazSU1mzo130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093341.RALdl3h9-SDFjS4jG3WuVFnrlAVFpWQmwcA7yazSU1mzo130_provenance.
• NP1093334.RA3Y4awTrz34uPR3zbpDK6BwIn-YIYD9F_yLsSxNzZ-Qk130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093334.RA3Y4awTrz34uPR3zbpDK6BwIn-YIYD9F_yLsSxNzZ-Qk130_provenance.
• NP1093336.RA2YLCPLLG2jiOZExiOhx1XqRl82R9P8qjM0c4TCHsjfg130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093336.RA2YLCPLLG2jiOZExiOhx1XqRl82R9P8qjM0c4TCHsjfg130_provenance.
• NP1093343.RA7EzI_1-XBRjHZ8unapPwQv2cT9mdlfvsJNL3JHga59w130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093343.RA7EzI_1-XBRjHZ8unapPwQv2cT9mdlfvsJNL3JHga59w130_provenance.